Periodontal disease: Repercussions in pregnant woman and newborn health-A cohort study.

ObjectiveTo investigate the repercussion of periodontal disease (PD) in the pregnant woman health and the complications during pregnancy and delivery, as well as negative outcomes for the newborn (as infections, prematurity, low birth weight and fetal growth restriction).MethodRetrospective cohort study, based on medical records of 142 pregnant women assisted at a prenatal service of usual risk between 2012-2014, with a dental evaluation for PD. Maternal variables, along with labor and newborn variables, were analyzed. The newborns were stratified into two groups: offspring of mothers with PD (subdivided into Severe Periodontal Disease-SPD) and offspring of mothers without PD. Each outcome was adjusted by a multiple logistic regression model, with significance for p-value ResultsAmong women diagnosed with SPD, the odds ratio for vulvovaginitis was 3.45 times greater (OR = 3.45, p-value = 0.050) and 5.59 times higher for premature rupture of membranes (OR = 5.59; p-value = 0.017). For neonates, the chance of fetal growth restriction was 11.53 times higher for pregnant women with SPD (OR = 11.53, p = 0.041).ConclusionThe periodontal disease increased the chance of neonatal and maternal negative outcomes, being the fetal growth restriction, vulvovaginitis and premature rupture of the membrane (PROM) the main results driven by the presence of Severe Periodontal Disease

Reemergence of Dengue Virus Serotype 3, Brazil, 2023

We characterized 3 autochthonous dengue virus serotype 3 cases and 1 imported case from 2 states in the North and South Regions of Brazil, 15 years after Brazil's last outbreak involving this serotype. We also identified a new Asian lineage recently introduced into the Americas, raising concerns about future outbreaks

Reemergence of Dengue Virus serotype 3, Brazil, 2023

Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Manaus, AM, Brazil.Centers for Disease Control and Prevention. San Juan, PR, USA.Laboratório Central de Saúde Pública de Roraima. Boa Vista, RR, Brazil.Laboratório Central de Saúde Pública de Roraima. Boa Vista, RR, Brazil.Fundação Oswaldo Cruz. Manaus, AM, Brazil.Fundação Oswaldo Cruz. Manaus, AM, Brazil.Fundação Oswaldo Cruz. Manaus, AM, Brazil.Fundação Oswaldo Cruz. Manaus, AM, Brazil.Fundação Oswaldo Cruz. Manaus, AM, Brazil.Fundação de Vigilância em Saúde Dra. Rosemary Costa Pinto. Manaus, AM, Brazil.Fundação de Medicina Tropical Dr Heitor Vieira Dourado. Manaus, AM, Brazil.Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Laboratório Central de Saúde Pública do Paraná. Curitiba, PR, Brazil.Laboratório Central de Saúde Pública do Paraná. Curitiba, PR, Brazil.Laboratório Central de Saúde Pública do Paraná. Curitiba, PR, Brazil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, BrazilFundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil.Fundação Oswaldo Cruz. Recife, PE, Brazil.Fundação Oswaldo Cruz. Recife, PE, Brazil.Fundação Oswaldo Cruz. Curitiba, PR, Brazil.Universidade Federal do Espírito Santo. Alegre, ES, Brazil.Florida Department of Health. Tampa, FL, USA.Florida Department of Health. Tampa, FL, USA.Centers for Disease Control and Prevention. San Juan, PR, USA.Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brazil.We characterized 3 autochthonous dengue virus serotype 3 cases and 1 imported case from 2 states in the North and South Regions of Brazil, 15 years after Brazil’s last outbreak involving this serotype. We also identified a new Asian lineage recently introduced into the Americas, raising concerns about future outbreaks

Portuguese guide lines for the use of biological agents in rheumatoid arthritis - october 2011 update

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of Rheumatoid Arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment (with a tumour necrosis factor antagonist, abatacept or tocilizumab) should be considered in RA patients with a disease activity score 28 (DAS 28) equal to or greater than 3.2 des pite treatment with at least 20mg-weekly-dose of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 3 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regi -mens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, defined by a DAS28 lower than 3.2,without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of at least 0.6 in the DAS28 score. After 6 months of treatment res ponse criteria is defined as a decrease greater than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opi -nion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituxi mab or tocilizumab).publishersversionpublishe